Cancer is one of the leading medical problems in the world. Towards this end, many researchers and scientists have massively invested in the battle against this disease. One such scientist is Clay Siegall of Seattle Genetics. At a young age in campus, Clay saw his relative suffering because of the side effects of chemotherapy. The relative had cancer, and the process of chemotherapy was intense to the point of having anemia. Clay’s drew inspiration from the suffering family member and decided to pursue better medical options that would offer less severe side effects from chemotherapy. That is why he founded Seattle Genetics. Dr. Clay Siegall is the founder of Seattle Genetics. His role in the organization involves managing all operations through executive leadership with the aim of acquiring a treatment solution for cancer.
Seattle Genetics was established in 1989. Since then, Clay Siegall has guided the management of the company to the peak of acquiring target therapy drugs that received the first FDA approval. ADCETRIS is the name of the drug conjugate, and since it was manufactured, it has received multiple approvals in over sixty countries thanks to Clay Siegall’s brilliance and commitment to saving lives. Through ADCETRIS, Seattle Genetics has developed multiple drug pipelines via strategic partnerships with pharmaceutical industries and companies like Bayer, Pfizer, Gsk, and Genentech.
The mechanism behind ADCETRIS is harnessing the targeting capacity of monoclonal antibodies. This is to deliver agents that promote cell-killing of the cancer cells. Also known as ADCs, ADCETRIS are intended to kill the targeted cells by sparing the non-targeted to reduce the side effects of chemotherapy. ADCETRIS is Seattle Genetics’ success story. It is available as Brentuximab vedotin in medical facilities, and it is accessible in many countries including the United States of America, Japan, and Canada as well as the commonwealth countries.
Dr. Clay Siegall is the founding father of Seattle Genetics. He is the chief executive officer and head of the board. His insightful leadership led Seattle Genetics into producing an FDA-approved drug to build a broad pipeline of drugs for cancer treatment. Clay is committed to developing less painful chemotherapies through revolutionary treatment methods like ADCETRIS.